Catalyst Pharmaceuticals, Inc.
Symbool: CPRX
NASDAQ
14.72
USDMarktprijs vandaag
21.9975
Koers/Winst Verhouding
-0.6049
Koers/Winst Groei Verhouding
1.73B
MRK Kapitalisatie
- 0.00%
DIV Rendement
Catalyst Pharmaceuticals, Inc. (CPRX) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2002 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 585.64 | 137.6 | 298.4 | 191.3 | |||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 19.8 | |||||||||||||||||||||
balance-sheet.row.net-receivables | 177.76 | 53.5 | 10.4 | 6.6 | |||||||||||||||||||||
balance-sheet.row.inventory | 45.76 | 15.6 | 6.8 | 7.9 | |||||||||||||||||||||
balance-sheet.row.other-current-assets | 20.18 | 12.5 | 5.2 | 4.4 | |||||||||||||||||||||
balance-sheet.row.total-current-assets | 851.23 | 219.3 | 320.8 | 210.1 | |||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 15.3 | 3.7 | 3.6 | 4 | |||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.intangible-assets | 720.84 | 194 | 32.5 | 0 | |||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 720.84 | 194 | 32.5 | 0 | |||||||||||||||||||||
balance-sheet.row.long-term-investments | 396.9 | 16.5 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.tax-assets | 119.5 | 38.3 | 18.7 | 23.7 | |||||||||||||||||||||
balance-sheet.row.other-non-current-assets | -367.51 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 885.02 | 252.6 | 54.8 | 27.7 | |||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-assets | 1736.24 | 471.9 | 375.6 | 237.8 | |||||||||||||||||||||
balance-sheet.row.account-payables | 27.2 | 14.8 | 4 | 2.8 | |||||||||||||||||||||
balance-sheet.row.short-term-debt | 1.43 | 0.4 | 0.3 | 0.3 | |||||||||||||||||||||
balance-sheet.row.tax-payables | 24.14 | 0.7 | 8.7 | 0.1 | |||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 13.31 | 3.2 | 3.6 | 3.9 | |||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | -1.3 | 0 | |||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.79 | - | - | - | |||||||||||||||||||||
balance-sheet.row.other-current-liab | 113.97 | 60.2 | 53.3 | 0.2 | |||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 47.78 | 8 | 17.6 | 3.9 | |||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 14.03 | 3.2 | 3.6 | 3.9 | |||||||||||||||||||||
balance-sheet.row.total-liab | 290.86 | 84 | 75.2 | 31 | |||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.common-stock | 0.43 | 0.1 | 0.1 | 0.1 | |||||||||||||||||||||
balance-sheet.row.retained-earnings | 404.32 | 121.3 | 49.9 | -26.3 | |||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.06 | 0 | 0 | -0.1 | |||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1040.58 | 266.5 | 250.4 | 233.2 | |||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 1445.38 | 387.9 | 300.4 | 206.8 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1736.24 | 471.9 | 375.6 | 237.8 | |||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-equity | 1445.38 | 387.9 | 300.4 | 206.8 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1736.24 | - | - | - | |||||||||||||||||||||
Total Investments | 396.9 | 16.5 | 0 | 19.8 | |||||||||||||||||||||
balance-sheet.row.total-debt | 14.4 | 3.6 | 3.9 | 3.9 | |||||||||||||||||||||
balance-sheet.row.net-debt | -571.24 | -134.1 | -294.5 | -167.6 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 71.41 | 71.4 | 83.1 | 39.5 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 32.88 | 33.1 | 1.2 | 0.2 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | -17.82 | -17.8 | 4.9 | 9.3 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 14.25 | 14.3 | 7.9 | 6.1 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | -37.32 | -37.3 | 13.7 | 5 | ||||||||||||||||||||
cash-flows.row.account-receivables | -43.08 | -43.1 | -3.8 | -0.6 | ||||||||||||||||||||
cash-flows.row.inventory | -4.74 | -4.7 | 1.1 | -3.2 | ||||||||||||||||||||
cash-flows.row.account-payables | 10.82 | 10.8 | 1.2 | -1.5 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 25.34 | -0.3 | 15.3 | 10.4 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 80.2 | 79.9 | 5.2 | 0.3 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 143.6 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -115.52 | -198.5 | 0 | -1 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 10 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | -13.46 | -13.5 | -10 | -10 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 19.2 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | -243.81 | -81.5 | -10 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -293.5 | -293.5 | 9.2 | -11 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 2.79 | 2.8 | 4.1 | 4.1 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -6.9 | -12.1 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | -13.65 | -13.6 | 4.5 | -0.2 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -10.86 | -10.9 | 1.7 | -8.1 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | -160.76 | -160.8 | 127 | 41.2 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 585.64 | 137.6 | 298.4 | 171.4 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 746.4 | 298.4 | 171.4 | 130.2 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 143.6 | 143.6 | 116 | 60.4 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | -115.52 | -198.5 | 0 | -1 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 28.08 | -54.9 | 116 | 59.4 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 398.2 | 398.2 | 214.2 | 140.8 | ||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 61.03 | 84.5 | 34.4 | 21.9 | ||||||||||||||||||||||
income-statement-row.row.gross-profit | 337.18 | 313.7 | 179.8 | 118.9 | ||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
income-statement-row.row.research-development | 93.15 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 47.02 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 86.69 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.other-expenses | 12.53 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.operating-expenses | 250.37 | 226.9 | 78 | 66.6 | ||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 311.39 | 311.4 | 112.4 | 88.4 | ||||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 3.6 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -4.1 | 0 | ||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 86.69 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 7.7 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 12.53 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 7.7 | 7.7 | 2.9 | 0.3 | ||||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -4.1 | 0 | ||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 32.81 | 33.1 | 1.2 | 0.2 | ||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 119.62 | - | - | - | ||||||||||||||||||||||
income-statement-row.row.operating-income | 86.81 | 86.8 | 101.8 | 52.4 | ||||||||||||||||||||||
income-statement-row.row.income-before-tax | 94.51 | 94.5 | 104.7 | 52.7 | ||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 23.1 | 23.1 | 21.6 | 13.2 | ||||||||||||||||||||||
income-statement-row.row.net-income | 71.41 | 71.4 | 83.1 | 39.5 |
Vaak gestelde vragen
Wat is Catalyst Pharmaceuticals, Inc. (CPRX) totale activa?
Catalyst Pharmaceuticals, Inc. (CPRX) totale activa is 471907000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 213256000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.847.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.179.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.218.
Wat is Catalyst Pharmaceuticals, Inc. (CPRX) nettowinst (netto-inkomen)?
De nettowinst is 71410000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 3557000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 226860000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 137636000.000.